Company Overview

Allurion Technologies Inc. is a medical device company focused on non-surgical weight loss and metabolic health solutions. The company operates within the medical devices and digital health industries, with a primary emphasis on obesity management. Its core offering is the Allurion Balloon, a swallowable, procedure-less gastric balloon designed to aid weight loss without surgery or endoscopy, combined with a digitally enabled behavior-change platform.

The company’s primary revenue drivers are sales of the Allurion Balloon Program, which integrates the balloon, remote patient monitoring, artificial intelligence–driven coaching, and clinical support tools for healthcare providers. Allurion serves physicians, weight-loss clinics, and hospitals, with patients as the ultimate end users. Its strategic differentiation lies in offering a fully non-invasive, endoscopy-free solution supported by proprietary digital monitoring and data analytics. Founded in 2009 and originally known as Elira Pharmaceuticals, the company rebranded as Allurion Technologies and expanded internationally before becoming publicly listed in 2023 following a business combination transaction.

Business Operations

Allurion generates revenue primarily through the sale of its Allurion Balloon Program to licensed healthcare providers, who offer the program to patients as a comprehensive weight-loss solution. Operations include device manufacturing, software development, clinical training, and ongoing digital health services. The company integrates proprietary technologies such as the Allurion Balloon, the Allurion Virtual Care Suite, and the Allurion Scale, which together enable remote patient monitoring and data-driven weight management.

The company operates internationally, with commercial activities across Europe, the Middle East, Asia-Pacific, and Latin America, and ongoing regulatory and market development efforts in the United States. Allurion sells directly in certain markets and through distributors in others. Public disclosures indicate no reliance on a single customer or distributor for a majority of revenue. Data on joint ventures is inconclusive based on available public sources.

Strategic Position & Investments

Allurion’s strategic direction centers on expanding access to non-invasive obesity treatment while building a recurring, data-enabled healthcare platform. Growth initiatives include geographic expansion, broader physician adoption, and continued enhancement of its digital ecosystem using artificial intelligence and machine learning to improve patient outcomes. The company has emphasized clinical evidence generation and post-market studies to support regulatory approvals and reimbursement discussions.

Investment priorities include product innovation, software development, and scaling manufacturing capabilities. Allurion has not disclosed a large portfolio of acquired companies; growth has primarily been organic. Subsidiary operations support regional commercialization and regulatory compliance. Public filings reference continued investment in emerging digital health capabilities, though specific financial commitments vary by period and are detailed in SEC filings.

Geographic Footprint

Allurion is headquartered in Boston, Massachusetts, and maintains a broad international footprint. The company has significant market presence in Western Europe, including countries such as France, Germany, Italy, and Spain, as well as operations across the Middle East, Asia-Pacific, and Latin America. These regions collectively represent the majority of current commercial activity.

While the United States represents a strategically important market, commercialization has historically been limited pending regulatory milestones, with international markets contributing most revenues. The company maintains regional offices, distribution partners, and clinical networks to support localized operations and physician engagement across multiple continents.

Leadership & Governance

Allurion was founded by entrepreneur and biomedical innovator Shantanu Gaur, who continues to play a central role in shaping the company’s long-term vision. Leadership emphasizes clinically validated innovation, global scalability, and technology-enabled care delivery. The governance structure aligns with U.S. public company standards following its listing, with oversight provided by a board of directors and executive leadership team.

Key executives include:

• Shantanu Gaur – Founder and Chief Executive Officer
• Dr. Salvatore Vaccaro – Chief Medical Officer
• Michel Gilly – Chief Financial Officer
• Daniel Flores – Chief Operating Officer
• Christopher Larkin – Chief Legal and Compliance Officer

Leadership philosophy focuses on expanding non-surgical obesity treatment globally while leveraging digital health infrastructure to improve patient adherence, outcomes, and scalability.